Important considerations regarding the sequencing of novel therapies for gastric cancer based on updates presented at the ASCO 2020 Virtual Meeting.
Data from the following clinical trials is discussed:
Pembrolizumab vs paclitaxel for previously treated pts with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase 3 KEYNOTE-061 trial. (Fuchs CS, et al. ASCO 2020. Abstract 4503)
KEYNOTE-158: FDA approval of pembrolizumab based on tumor mutational burden-high (TMB-high) (FDA.gov; Marabelle A, et al. J Clin Oncol. 2020)WES, cut-off 175 mutations/exome (Fuchs CS, et al. ASCO 2020. Abstract 4512)
FoundationOne CDx (F1CDx); Foundation Medicine cut-off 10 mut/MB (Shitara K, et al. ASCO 2020. Abstract 4537)
T-DXd; DS-8201 in pts with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01). (Shitara K, et al. ASCO 2020. Abstract 4513)
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. (Safran H, et al. ASCO 2020. Abstract 4500)
Perioperative trastuzumab and pertuzumab in combination with FLOT for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase 2 trial of the AIO. (Dieter Hofheinz R, et al. ASCO 2020. Abstract 4502)
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for pts with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase 2 RAMIRIS Study of the AIO. (Lorenzen S, et al. ASCO 2020. Abstract 4514)